Analyst Weekly, October 6, 2025
After a quiet few months, Bitcoin may be gearing up for its favourite seasonal commerce: the fourth-quarter comeback. Crypto’s greatest three-month stretch traditionally begins proper about now, with median positive aspects above 50% from October by way of December. The setup seems to be acquainted: yields are falling, volatility is low, and merchants are as soon as once more attempting to find risk-on belongings because the Fed’s easing cycle positive aspects traction.
Bitcoin This fall 2025 Outlook
Bitcoin enters the fourth quarter with energy, coupled with indicators of warning. October has earned its “UpTober” fame, with double-digit positive aspects in most cycles since 2013. The post-halving dynamic and the psychological part of merchants anticipating rallies might act as catalysts. Nonetheless, whereas the asset stays inside a structurally bullish technical transfer, we observe some basic indicators of maturity. Though projections point out that an extension towards 150,000 is feasible, every further leg will increase the chance of exhaustion. On-chain indicators affirm this ambivalence, because the MVRV Z-score stays removed from historic peaks, however long-term holders are promoting and whales are starting to scale back publicity.
In the meantime, the tokenization wave is gaining pace. Stablecoins surpassed $300 billion in market capitalization for the primary time, with quarterly progress outpacing many conventional asset courses. Narratives to look at embody “agentic” funds pushed by AI with stablecoins as the bottom layer, interoperability amongst a number of issuers and platforms, and new regulatory tensions from Hong Kong to Europe. In parallel, CME is increasing its derivatives providing (with Solana and XRP choices this October, and the promise of 24/7 buying and selling in 2026), whereas the SEC’s simplification in ETF approval opens the door to merchandise based mostly on belongings far much less liquid than bitcoin.
Altogether, this attracts a well-known late-cycle image. When altcoins outperform BTC, when memecoins enter ETFs, when infrastructure tales dominate headlines, it’s extra usually a symptom of maturity than the beginning of a brand new part. Nothing prevents one final bullish leg, the market might properly set new highs in This fall, however the larger danger is {that a} macro shock or an fairness market downturn coincides with indicators of crypto exuberance, turning euphoria into volatility.
Thus, the fourth quarter combines seasonal and structural tailwinds with rising proof that the cycle is in its superior stage. The check will likely be whether or not institutional flows and the momentum of tokenization can offset the burden of macro dangers and investor overconfidence.
Healthcare’s Checkup: From Coverage Ache to Potential Acquire
Healthcare shares simply obtained a much-needed shot within the arm. The sector, which has trailed the S&P 500 for many of the previous two years, surged after information of a US–Pfizer deal that might reset expectations on drug pricing and tariffs.
Underneath the settlement, Pfizer agreed to decrease costs on Medicaid medicine in trade for 3 years of tariff aid, a shock transfer that might trigger different pharma giants to observe swimsuit.
Investor Takeaway: With Pfizer pledging $70B in new US investments, agreeing to decrease drug costs, and the White Home shelving 100% drug tariffs, the sector’s coverage headache is easing. Different corporations like Johnson & Johnson, AstraZeneca, and Roche are following swimsuit, highlighting a broader “Made in America” healthcare pattern that might assist jobs and capability enlargement. For long-term traders, that’s a dose of stability the market’s been ready for. For the previous few years, drugmakers have confronted fixed uncertainty over how aggressively Washington may attempt to reduce or management prescription drug costs. That uncertainty, about potential caps, negotiations, or tariffs, have made traders hesitant to purchase healthcare shares, as a result of it was unclear how far the federal government would go.
A Rally on the Prescription Pad
Healthcare shares rallied final week, with huge names like Pfizer, Eli Lilly, and AbbVie main, as merchants guess on a This fall rebound. The coverage enhance is sparking hopes for a “catch-up commerce” as traders rotate into lagging defensive sectors.
SMID Cap Healthcare Shares Get a Tax-Time Enhance
Washington’s new One Large Stunning Invoice (OBBB) will give smaller well being and biotech corporations a significant tax break. Firms can now instantly expense their R&D prices, as an alternative of spreading them out over years.
That’s a recreation changer for smaller healthcare innovators, particularly for those that spend closely on analysis however don’t but have large income to offset it. It successfully lowers their tax invoice and frees up money, letting them make investments sooner in new medicine and applied sciences.
Shares That Stand Out
Shares might achieve most from this setup are those that spend most on R&D, equivalent to:
Roviant Sciences ($ROIV) – heavy R&D focus and pipeline-driven mannequin.ACADIA Prescribed drugs ($ACAD) – smaller-cap biotech with excessive R&D-to-sales ratio.Arrowhead Prescribed drugs ($ARWR) – early-stage biotech leveraging RNAi tech, robust beneficiary of upfront expensing.Dynavax Applied sciences ($DVAX) – vaccine developer with substantial US-based R&D.Jazz Prescribed drugs ($JAZZ) – robust reinvestment profile, mid-cap title with home operations.
What May Maintain the Rally for the Sector Going
Past politics, fundamentals are enhancing. The brand new R&D expensing guidelines from this summer season’s tax invoice enable healthcare and biotech corporations, particularly for small and mid-cap gamers, to put in writing off analysis prices instantly, boosting near-term profitability. Add in Fed charge cuts and a backdrop of falling inflation, and the setup seems to be more and more supportive for long-duration sectors like well being and biotech. Lastly, ETF flows have been damaging, suggesting many traders already capitulated, a contrarian setup.
Past Weight Loss: GLP-1s Energy a Lasting Pharma Transformation
GLP-1s have reshaped pharma into one of the crucial highly effective progress tales in world markets, creating tech-style winners like Eli Lilly and Novo Nordisk. Lilly is up practically 400% in 5 years and Novo stays far forward of friends, displaying that even with short-term pullbacks and job cuts, the long-term trajectory is unbroken. That’s as a result of the leaders aren’t simply driving a one-drug increase: they’re broadening entry with oral formulations, defending share in weight problems and diabetes regardless of pricing and formulary noise, and constructing sturdiness with progress in oncology and immunology.
For traders, which means GLP-1s have clearly shifted from a disruptive area of interest into a various, multi-franchise progress engine, the place the chance lies in putting the proper steadiness between chasing disruptive upside and anchoring in stability.
This communication is for info and schooling functions solely and shouldn’t be taken as funding recommendation, a private suggestion, or a suggestion of, or solicitation to purchase or promote, any monetary devices. This materials has been ready with out making an allowance for any specific recipient’s funding goals or monetary scenario and has not been ready in accordance with the authorized and regulatory necessities to advertise impartial analysis. Any references to previous or future efficiency of a monetary instrument, index or a packaged funding product will not be, and shouldn’t be taken as, a dependable indicator of future outcomes. eToro makes no illustration and assumes no legal responsibility as to the accuracy or completeness of the content material of this publication.
